Fate Therapeutics News

Fate Therapeutics Currently Down 11 Consecutive Days, on Track for Record Losing Streak -- Data Talk

Fate Therapeutics, Inc. (FATE) is currently at $4.36, down $0.18 or 3.96% --Would be lowest close since Jan. 18, 2024, when it closed at $4.33 --Currently down 14 of the past 15 days --Currently do

Dow JonesApr 24 11:13 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)

TipRanksApr 24 04:50 ET

Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk

Fate Therapeutics, Inc. (FATE) is currently at $4.58, down $0.21 or 4.29% --Would be lowest close since Jan. 26, 2024, when it closed at $4.56 --Currently down 13 of the past 14 days --Currently do

Dow JonesApr 23 14:09 ET

Express News | Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target

Moomoo 24/7Apr 23 13:12 ET

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B Cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.

GlobeNewswireApr 22 16:30 ET

Why Investors Shouldn't Be Surprised By Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Share Price Plunge

Fate Therapeutics, Inc. (NASDAQ:FATE) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped

Simply Wall StApr 19 06:37 ET

Fate Therapeutics Files to Sell 3.64M Shares for Holders

Seeking AlphaApr 18 16:32 ET

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)

TipRanksApr 11 06:20 ET

Express News | Needham Reiterates Hold on Fate Therapeutics

Moomoo 24/7Apr 11 06:09 ET

FATE, ALPN and RLAY Are Among After Hour Movers

Seeking AlphaApr 10 17:20 ET

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by

BenzingaApr 10 16:31 ET

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Yahoo FinanceApr 6 02:17 ET

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-

Fate TherapeuticsApr 3 00:00 ET

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripoten

Fate TherapeuticsApr 2 00:00 ET

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Yahoo FinanceMar 29 11:30 ET

Fate Therapeutics Is Maintained at Underperform by B of A Securities

Fate Therapeutics Is Maintained at Underperform by B of A Securities

Dow JonesMar 28 14:24 ET

Express News | B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6

Moomoo 24/7Mar 28 14:13 ET

Fate Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 -19.46% B of A Securities $2 → $6 Maintains Underperform 03/19/2024 -6.04% HC Wainwright & Co.

BenzingaMar 28 14:12 ET

Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns

TipRanksMar 28 04:58 ET

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Yahoo FinanceMar 27 11:30 ET